media – Page 130 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

ANKE Bio marketing management team went to Jingze Bio to promote the cooperation between the two sides to reach substantial progress

On April 18, 2024, Mr. Yang Jun, General Manager of ANKE Bio’s Reproductive and Antiviral Division, together with the division’s management team, went to Chengdu Jingze Bio-Pharmaceutical Company Limited to deepen the exchange and cooperation. Mr. Peng Hongwei, Chairman of Jingze Biologicals, Mr. Peng Hui, Director of Jingze Biologicals, and other relevant department heads warmly received them and accompanied them to the seminar. In the project cooperation docking forum held later, both sides discussed and exchanged around the current industry dynamics of Jingze Bio’s core product JZB30, the market competition environment, the progress of the product listing, the open mode of cooperation and other aspects, and reached a unanimous consensus. This marks that the cooperation and promotion of the product has made substantial progress, and the pragmatic cooperation between the two sides has entered into a more comprehensive and deeper new stage, while the common development of the two sides, ...
- Source: drugdu
- 89
- April 23, 2024
Vertex’s pain drug suzetrigine advances in FDA approval process

Vertex Pharmaceuticals’ suzetrigine, previously named VX-548, is steadily advancing along its rolling submission approval pathway okayed by the US Food and Drug Administration (FDA) for moderate-to-severe acute pain. The company announced its plans to submit an NDA following positive Phase III results from two clinical trials investigating the drug in patients who had undergone bunionectomy (NCT05553366) or abdominoplasty (NCT05558410) surgery. Both trials met the primary endpoints, and suzetrigine demonstrated a favourable safety profile with no serious adverse events reported. Vertex has started the rolling submission process and aims to finish by Q2 2024. With FDA fast track and breakthrough therapy designations already secured for the drug to treat acute pain, Vertex is now focusing on neuropathic pain, where positive Phase II results have been achieved. Following a successful end-of-Phase II meeting with the FDA, Vertex is planning a Phase III pivotal programme for patients with diabetic peripheral neuropathy (DPN) later ...
- Source: drugdu
- 85
- April 23, 2024
Researchers introduce new AI tool to help clinicians capture uncertainty in medical images

The Tyche model could help clinicians and researchers capture crucial information in images Researchers from the Massachusetts Institute of Technology (MIT), the Broad Institute of MIT and Harvard, and Massachusetts General Hospital have introduced a new artificial intelligence (AI) tool to capture the uncertainty in a medical image. Funded by the National Institute of Health, the Eric and Wendy Schmidt Center and Quanta Computer, the Tyche machine-learning model could help clinicians and researchers capture crucial information. In biomedicine, AI models help clinicians by highlighting pixels that show signs of a certain disease or anomaly. However, these types of models usually only provide one answer. “Having options can help in decision-making” and “so it is important to take this uncertainty into account,” said MIT computer science PhD candidate, Marianne Rakic. Researchers developed Tyche after modifying a straightforward neural network architecture. After feeding the tool a few examples of segmentation tasks, such ...
- Source: drugdu
- 69
- April 23, 2024
New UK report highlights inequalities among people living with breast cancer

Breast cancer was responsible for 2.3 million diagnoses and 670,000 deaths globally in 2022 A new report led by the University of Cambridge and supported by the National Institute for Health and Care Research (NIHR) has highlighted inequalities among people living with breast cancer. Published by the Lancet Commission, the report sets out several recommendations to tackle these challenges in breast cancer and builds on previous evidence, new data and patient voices. According to the World Health Organization, breast cancer was responsible for 2.3 million diagnoses and 670,000 global deaths in 2022. Despite recent improvements in breast cancer, including advances in diagnosis and treatment, many people are still disproportionately affected. The commission revealed that progress in research and cancer management has led to a decrease of over 40% in breast cancer mortality, with estimates suggesting that the global breast cancer incidence will increase from 2.3 million new cases in 2020 ...
- Source: drugdu
- 82
- April 23, 2024
Vietnam Medipharm Expo 2024

Organiser: Ministry of Health of Vietnam Time:1 – 3 August 2024 address：Lawrence S. Ting Building 801 Nguyen Van Linh Parkway, Dist. 7 Ho Chi Minh City Vietnam Exhibition hall: Saigon Exhibition & Convention Center Product range: Medical products: medical equipment and instruments, medical consumables, medical dressings, surgical equipment, rescue equipment, diagnostic equipment and supplies, ophthalmic equipment and equipment, ENT equipment, dental equipment and supplies, medical reagents and equipment, medical health products and equipment, medical institutions and laboratory technical equipment, medical information and technical exchange, beauty equipment Analytical instruments: Optical analysis instruments, mass spectrometers, spectrometers, chromatographs, spectrometers, electrochemical analysis instruments, X-ray analysis instruments, gas chromatography, liquid chromatography, thermal analysis instruments, all kinds of portable instruments, surface analysis instruments, nuclear analysis instruments, elemental analysis instruments, process analysis instruments, composition analysis instruments, injection analysis instruments and other general analytical instruments Laboratory equipment: Laboratory instruments and equipment, laboratory automation and accessories, optical instruments and equipment, ...
- Source: drugdu
- 140
- April 23, 2024
IceCure submits final breast cancer cryoablation data to FDA

BY SEAN WHOOLEYIceCure Medical (Nasdaq:ICCM) announced today that it submitted final data to the FDA requesting marketing authorization for its ProSense system. Caesarea, Israel-based IceCure designed ProSense to deliver cryoablation that treats breast cancer in a 20-40-minute outpatient procedure. It seeks FDA authorization for treating patients with early-stage T1 invasive breast cancer with cryoablation and adjuvant hormone therapy. ProSense already holds FDA breakthrough device designation and has clearance in the U.S. for other indications. Those include treating benign tumors of the breast, and tumors in the kidney and liver. However, the FDA in 2022 denied IceCure’s de novo classification request for ProSense to treat patients with early-stage, low-risk breast cancer. In January of this year, the FDA agreed to reopen the de novo file. An affirmative response from the FDA provided IceCure with a potential pathway to clearance. The company submitted a five-year follow-up dataset from the ICE3 study and ...
- Source: drugdu
- 109
- April 22, 2024
UniDoc Brings AI-Powered Health Cube to Alaska

Mike Hollan The Health Cube will increase remote and virtual care options for populations living in remote areas. AI is helping to expand healthcare solutions to rural areas. While people living in or near highly populated areas tend to have more options when it comes to healthcare, the lack of options in rural areas can be a real issue. For patients living in a state like Alaska, getting access to the proper care can involve traveling long distances, delays in obtaining medication, and sometimes being unable to find the proper specialists. One way that the industry is attempting to solve this issue is by bringing more telehealth and virtual options to these areas. New technologies, such as AI, are making this easier, as the algorithms are better able to match patients with the proper care providers through virtual sessions, while also making it easier to find ways to get the ...
- Source: drugdu
- 103
- April 22, 2024
23andMe CEO plans to take company private

Dive Brief 23andMe CEO Anne Wojcicki plans to take the DNA testing company private, according to a Wednesday filing with the U.S. Securities and Exchange Commission. Wojcicki currently owns more than 20% of the firm’s total outstanding shares, and about 49% of voting rights. She plans to acquire all outstanding shares of the company. The CEO wants to maintain control of 23andMe and would not be willing to support any alternative transaction, according to the filing. Dive Insight 23andMe, which makes consumer genetic tests, has been looking at strategic alternatives as its shares have fallen. The firm went public in 2021 through a merger with a special purpose acquisition company valuing 23andMe at $3.5 billion. Its stock has traded below a dollar this year, down from its IPO price of $10 per share. 23andMe has also expanded into drug research by using its database built up through the DNA testing ...
- Source: drugdu
- 84
- April 22, 2024
Boston Scientific recalls blood-blocking agent linked to 2 deaths

Dive Brief Boston Scientific has recalled an agent used to block blood flow to specific vessels due to a safety problem that has been tied to seven injuries and two deaths, the Food and Drug Administration said Wednesday in a recall notice. The company wrote to customers in February to advise against delivering the agent via a commonly used method in some patients because of a risk of reduced blood flow to the bowel. Boston Scientific’s product, Obsidio Conformable Embolic, remains on the market, but the company advised healthcare providers to ensure information on the risk is easily accessible to all users. Dive Insight The solution flows like a liquid when force is applied, and then returns to a soft solid state when the force is removed. As a soft solid, the agent blocks blood vessels. Physicians use the product to block blood supply to tumors with large numbers of ...
- Source: drugdu
- 125
- April 22, 2024
ENTOD Pharma gets CDSCO approval for eye drops to treat presbyopia

ENTOD Pharmaceuticals received approval from CDSCO for PresVu, a treatment for presbyopia, by the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO). PresVu is a eye drop in India designed to alleviate the need for reading glasses among individuals grappling with presbyopia. Presbyopia, characterised by blurred near vision due to the decreased flexibility of the eye’s natural lens, primarily impacts individuals aged 40 and above. PresVu offers swift relief and temporary correction of vision problems associated with presbyopia. PresVu eye drops adjust rapidly to tear pH, ensuring sustained efficacy and safety for long-term use. The company completed development of these eye drops in late 2022 after which it was subjected to clinical testing in India. Reportedly, Phase 3 clinical trials carried out in India and the US have demonstrated PresVu’s efficacy in enhancing close-up vision within minutes of application, with effects lasting up to six hours. ...
- Source: drugdu
- 133
- April 22, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.